The stream · Daily digest
The stream: Monday, October 26, 2026
6 briefs from ClinicalTrials.gov and FDA, grouped by desk. Each is two sentences from one primary source, linked to it.
Machine-summarized from primary sources; not independently reported. How we use automation
Clinical trials · 3
-
Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll 1050 participants and begin on November 20, 2026. It compares HRS-6209 plus letrozole with dalpciclib or palbociclib plus aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment.
Source: ClinicalTrials.gov registry record, October 26, 2026
-
UNION trial shows 3-year event-free survival 91·3% vs 77·4%
In a prespecified interim analysis of 231 patients, the experimental group achieved a 3-year investigator-assessed event-free survival rate of 91·3% compared with 77·4% in the standard-of-care group (log-rank p=0·0029). Treatment-related serious adverse events occurred in 19% of experimental patients versus 13% of standard-of-care patients.
Source: PubMed record of a Phase III journal article, October 25, 2026
-
Pembrolizumab plus chemotherapy prolongs PFS versus monotherapy in high-PD-L1 NSCLC
In the PERSEE phase III trial, 321 patients with stage IV or unresectable stage III NSCLC and PD-L1 ≥50% were randomized to pembrolizumab alone or with platinum-based chemotherapy. Median progression-free survival was 16.1 months with combination versus 6.9 months with monotherapy (HR 0.56, 95% CI 0.43-0.74; P<0.001).
Source: PubMed record of a Phase III journal article, October 25, 2026
Policy · 2
-
Amgen APPOINTS David W. Gibbs to board of directors
The appointment is effective immediately and Gibbs will serve on the Audit Committee and Compensation and Management Development Committee. The Board will have 13 directors, 12 of whom are independent.
Source: Company press release (PR Newswire), October 26, 2026
-
Abbott launches whole-genome sequencing Oncodetect MRD test
Abbott announced the commercial availability of its next-generation Oncodetect MRD test, a personalized, tumor-informed, whole-genome sequencing test that tracks up to 5,000 patient-specific variants with a limit of detection below one part per million. The company said the test could be used for patients with solid tumors.
Source: Company press release (PR Newswire), October 26, 2026
Approvals · 1
-
FDA approves talazoparib with enzalutamide for metastatic prostate cancer
On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test. The TALAPRO-3 trial showed median radiographic progression-free survival not reached (95% CI: NR, NR) versus 45.8 months (95% CI: 37.7, NR) with a hazard ratio of 0.48 [95% CI: 0.36, 0.65]; p<0.0001.
Source: FDA approval notification, October 26, 2026